The aim of the EuroSpA Research Collaboration Network
The aim of the EuroSpA Research Collaboration Network (RCN) is to jointly address research questions in SpA including, but not limited to, real world effectiveness and safety profiles of biologic therapies. This is done by retrospectively and prospectively collecting real life patient data from European registers.
The collaboration promotes opportunities to identify unmet needs in the treatment of SpA patients by utilizing high-quality data from existing patient registries.
Our aims are in line with the EMA initiative for patient registries and are consistent with discussions at the EMA workshop “How to make better use of patient registries to collect high-quality data on medicines” held in London on October 28th, 2016 in London.
EuroSpA RCN Scope
Currently the collaboration consists of 19 registries (see map).
There is a recognized openness to include other interested registries and to other parties such as health authorities (EMA and local regulatory bodies) and patient organizations, although the extent of their involvement will need to be further defined.
Acknowledgements
Novartis Pharma AG for supporting the EuroSpA collaboration.
UCB Biopharma SRL for supporting the EuroSpA collaboration.
AbbVie Inc for supporting the EuroSpA collaboration.
Registries that contribute data to the collaboration
ARC (Netherlands)
ATTRA (Czech Republic)
BIOBADASER (Spain)
Biorx.si (Slovenia)
BSRBR-AS/BSR-PsA (United Kingdom)
DANBIO (Denmark)
ERSBTR (Estonia)
GISEA (Italy)
ICEBIO (Iceland)
NOR-DMARD (Norway)
RABBIT-SpA (Germany)
Reuma.pt (Portugal)
ROBFIN (Finland)
RRBR (Romania)
SCQM (Switzerland)
SRQ (Sweden)
TURKBIO (Turkey)
UCRCR (Crete)
POL-DMARD (Poland)
The most recent EuroSpA publications
EuroSpA publication 6.1
Real-World Six- and Twelve-Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in [...]
EuroSpA publication 6.2
Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data [...]
EuroSpA publication 2.3
Impact of discordance between patient’s and evaluator’s global assessment on treatment outcomes in 14 868 patients with spondyloarthritis [...]
EuroSpA publication 3.1
Effectiveness and treatment retention of TNF inhibitors when used as monotherapy versus comedication with csDMARDs in 15 332 patients [...]
EuroSpA publication 1.1
Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA [...]
To see full list, please click Publications in top menu
EuroSpA Research Collaboration Network explained by chairpersons Professor Merete Lund Hetland and Professor Mikkel Østergaard
Why is it meaningful to be a part of EuroSpA? – an interview with 8 members of the Scientific Committee
EuroSpA meetings
EuroSpA Scientific Committee consists of representatives from the 19 participating registries, who meets for hybrid meetings twice yearly in Copenhagen and online.
EuroSpA F2F meeting, Spring 2026
EuroSpA F2F meeting, Spring 2025
EuroSpA F2F meeting, Spring 2024
